Ceva completes deal to acquire portfolio of Merial swine & cattle vaccines and nonsteroidal anti-inflammatories from Boehringer Ingelheim >

19 January 2017: Ceva Santé Animale today completed the acquisition of a diversified portfolio of products, including swine and cattle vaccines and multi-species nonsteroidal anti-inflammatories from Boehringer Ingelheim .

Ceva acquires Hertape and Inova to enter brazil’s top 5 animal health companies >

Move will increase the group global vaccine footprint with significant entry into the ruminant, Foot and Mouth disease market and a first entry into companion animal vaccines.

C.H.I.C.K Program receives the 1st independently audited quality recognition >

For the first time, an AH company services program receives internationally recognized quality approval from Bureau Veritas.

Ceva posts strong double-digit organic growth once again in first half of 2016 >

Consolidated sales of the Ceva Group reached €455m at the end of June 2016.

Ceva acquires Biovac >

Move will reinforce group’s AMR strategy to find alternative solutions to use of antibiotics.

Ceva Posts Strong Double-Digit growth again in 2014 >

Consolidated sales of the Ceva Group reached €766m at the end of 2014, representing growth of 23% and +14.1% at a constant perimeter and exchange rates.

Another investment of HUF 2 billion from Ceva-Phylaxia >

Ceva-Phylaxia, one of the veterinary market leaders expands its vaccine production plant again.

50 billionth domestic poultry vaccine reaches completion >

As a market leader, the so-called immune complex vaccines against one of the most frequent catching disease that affects chickens are produced in Hungary.

Press Release: The big tick map is to come >

Press Release: The new canine disease can be prevented >